$WVE
Wave Life Sciences Ltd.

2020 Q3 Form 10-Q Financial Statement

#000156459020052211 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q3
Revenue $3.450M $3.030M $2.929M
YoY Change 17.79% -60.28% -34.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.590M $10.21M $12.52M
YoY Change -23.4% -12.29% 27.11%
% of Gross Profit
Research & Development $28.28M $31.48M $44.59M
YoY Change -36.58% -24.34% 35.61%
% of Gross Profit
Depreciation & Amortization $2.040M $2.020M $1.940M
YoY Change 5.15% 8.6% 32.88%
% of Gross Profit
Operating Expenses $37.87M $41.68M $57.11M
YoY Change -33.69% -21.72% 33.66%
Operating Profit -$54.18M
YoY Change 41.71%
Interest Expense $40.00K $140.0K $1.210M
YoY Change -96.69% -90.91% 14.15%
% of Operating Profit
Other Income/Expense, Net $1.280M -$2.005M $2.250M
YoY Change -43.11% -194.13% -589.13%
Pretax Income -$33.10M -$40.53M -$50.73M
YoY Change -34.75% -3.36% 34.81%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$33.10M -$40.53M -$50.73M
YoY Change -34.75% -3.37% 34.8%
Net Earnings / Revenue -959.42% -1337.56% -1731.85%
Basic Earnings Per Share
Diluted Earnings Per Share -$862.9K -$1.151M -$1.480M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $216.4M $94.10M $209.0M
YoY Change 3.54% -62.79% -0.71%
Cash & Equivalents $220.0M $216.4M $212.7M
Short-Term Investments
Other Short-Term Assets $12.10M $16.33M $21.20M
YoY Change -42.92% -2.23% 66.93%
Inventory
Prepaid Expenses $6.452M
Receivables $30.00M $30.00M $20.00M
Other Receivables $0.00 $16.30M $0.00
Total Short-Term Assets $258.4M $146.8M $250.3M
YoY Change 3.24% -49.3% 7.33%
LONG-TERM ASSETS
Property, Plant & Equipment $47.80M $50.30M $55.70M
YoY Change -14.18% 31.12% 47.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.800M $6.800M $11.20M
YoY Change -66.07% -21.84% 202.7%
Total Long-Term Assets $51.70M $57.17M $96.90M
YoY Change -46.65% -40.42% 6.02%
TOTAL ASSETS
Total Short-Term Assets $258.4M $146.8M $250.3M
Total Long-Term Assets $51.70M $57.17M $96.90M
Total Assets $310.1M $204.0M $347.2M
YoY Change -10.69% -47.09% 6.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.700M $13.90M $20.20M
YoY Change -51.98% 21.25% 68.33%
Accrued Expenses $2.203M $11.70M $16.90M
YoY Change -86.96% -20.41% 77.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $109.7M $110.5M $133.4M
YoY Change -17.77% -10.95% 6.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $84.30M $90.10M $91.20M
YoY Change -7.57% 4649.6% 6000.33%
Total Long-Term Liabilities $84.30M $90.10M $91.20M
YoY Change -7.57% -3.5% 8.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $109.7M $110.5M $133.4M
Total Long-Term Liabilities $84.30M $90.10M $91.20M
Total Liabilities $193.9M $200.6M $224.6M
YoY Change -13.67% -7.75% 6.9%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.2M -$4.489M $114.8M
YoY Change
Total Liabilities & Shareholders Equity $310.1M $204.0M $347.2M
YoY Change -10.69% -47.09% 6.97%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q3
OPERATING ACTIVITIES
Net Income -$33.10M -$40.53M -$50.73M
YoY Change -34.75% -3.37% 34.8%
Depreciation, Depletion And Amortization $2.040M $2.020M $1.940M
YoY Change 5.15% 8.6% 32.88%
Cash From Operating Activities -$20.17M -$38.15M -$43.68M
YoY Change -53.82% 15.85% 50.57%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$140.0K -$460.0K
YoY Change -86.96% -91.25% -86.43%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$60.00K -$140.0K -$460.0K
YoY Change -86.96% -91.25% -86.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 142.5M 11.39M 250.0K
YoY Change 56908.0% -7218.75% -81.48%
NET CHANGE
Cash From Operating Activities -20.17M -38.15M -43.68M
Cash From Investing Activities -60.00K -140.0K -460.0K
Cash From Financing Activities 142.5M 11.39M 250.0K
Net Change In Cash 122.3M -26.90M -43.89M
YoY Change -378.63% -22.46% 41.35%
FREE CASH FLOW
Cash From Operating Activities -$20.17M -$38.15M -$43.68M
Capital Expenditures -$60.00K -$140.0K -$460.0K
Free Cash Flow -$20.11M -$38.01M -$43.22M
YoY Change -53.47% 21.32% 68.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-47493000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
20858000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-40528000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-4489000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93744000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3284000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
5020000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
253000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-50726000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
114773000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
3999000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
702000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
23000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-33100000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
108241000
us-gaap Profit Loss
ProfitLoss
-121121000
us-gaap Profit Loss
ProfitLoss
-136868000
wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
1376000
wve Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
1187000
us-gaap Depreciation
Depreciation
6097000
us-gaap Depreciation
Depreciation
5584000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14522000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-20000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10000000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1660000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-4147000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-15106000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
16038000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
562000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7471000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6003000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-998000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10638000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13583000
wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2382000
wve Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2066000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-301000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-349000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84567000
CY2019Q4 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2493000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-126991000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
781000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
69205000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10182000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2572000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-781000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2572000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93744000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161792000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
722000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1850000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
171000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
154519000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163642000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34208000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150808000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
178444000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
220013000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
212652000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
216400000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#212529;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has reclassified certain prior period financial statement amounts to conform to its current period presentation. These reclassifications have not changed the results of operations of prior periods.</p>
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16185000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.22
us-gaap Restructuring Charges
RestructuringCharges
3400000
CY2020Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
200000
us-gaap Payments For Restructuring
PaymentsForRestructuring
3100000
CY2020Q3 us-gaap Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
300000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6980000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8662000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2203000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5030000
CY2020Q3 wve Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
999000

Files In Submission

Name View Source Status
0001564590-20-052211-index-headers.html Edgar Link pending
0001564590-20-052211-index.html Edgar Link pending
0001564590-20-052211.txt Edgar Link pending
0001564590-20-052211-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g15xibmjom2x000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-10q_20200930.htm Edgar Link pending
wve-10q_20200930_htm.xml Edgar Link completed
wve-20200930.xsd Edgar Link pending
wve-20200930_cal.xml Edgar Link unprocessable
wve-20200930_def.xml Edgar Link unprocessable
wve-20200930_lab.xml Edgar Link unprocessable
wve-20200930_pre.xml Edgar Link unprocessable
wve-ex101_100.htm Edgar Link pending
wve-ex311_9.htm Edgar Link pending
wve-ex312_10.htm Edgar Link pending
wve-ex32_7.htm Edgar Link pending